|
|
xi | |
About the Editors |
|
xiii | |
Preface |
|
xv | |
|
Part 1 The Rationale to Reach the Brain |
|
|
|
Chapter 1 Anatomy and Physiology of the Blood--Brain Barrier |
|
|
3 | (12) |
|
|
|
|
3 | (1) |
|
|
4 | (2) |
|
3 BBB Developmental Steps |
|
|
6 | (1) |
|
4 Transport Across the BBB |
|
|
7 | (4) |
|
|
11 | (4) |
|
|
11 | (1) |
|
|
11 | (4) |
|
Chapter 2 Blood--Brain Barrier: Genomics, Proteomics, Disease Targets, and Drug Delivery |
|
|
15 | (20) |
|
|
|
|
15 | (1) |
|
2 Blood--Brain Barrier Genomics |
|
|
16 | (3) |
|
3 Blood--Brain Barrier Proteomics |
|
|
19 | (1) |
|
|
20 | (1) |
|
|
21 | (5) |
|
|
26 | (9) |
|
|
26 | (1) |
|
|
27 | (8) |
|
Chapter 3 Brain and the Drug Transporters |
|
|
35 | (34) |
|
|
|
|
|
35 | (1) |
|
|
36 | (14) |
|
|
50 | (19) |
|
|
51 | (1) |
|
|
51 | (18) |
|
Chapter 4 Drug Delivery to the Brain: Pharmacokinetic Concepts |
|
|
69 | (24) |
|
|
|
|
69 | (1) |
|
|
70 | (7) |
|
3 Intrabrain Distribution |
|
|
77 | (2) |
|
|
79 | (14) |
|
|
79 | (2) |
|
|
81 | (12) |
|
Part 2 Nose-to-Brain Drug Delivery |
|
|
|
Chapter 5 Nasal Physiology and Drug Transport |
|
|
93 | (10) |
|
|
|
93 | (1) |
|
|
94 | (2) |
|
3 Nasal Transport Mechanisms |
|
|
96 | (2) |
|
4 Factors Affecting Nose-to-Brain Transport |
|
|
98 | (1) |
|
5 Principles of Drug Administration |
|
|
99 | (1) |
|
|
99 | (4) |
|
|
100 | (1) |
|
|
100 | (3) |
|
Chapter 6 Challenges of the Nose-to-Brain Route |
|
|
103 | (14) |
|
|
|
103 | (1) |
|
|
104 | (1) |
|
3 Overcoming Barriers in Nasal Drug Delivery |
|
|
105 | (2) |
|
4 In Vitro and In Vivo Models for Nasal Drug Delivery |
|
|
107 | (1) |
|
|
108 | (9) |
|
|
109 | (1) |
|
|
109 | (8) |
|
Part 3 Nanoscience in Targeted Brain Drug Delivery |
|
|
|
Chapter 7 Nanoscience in Targeted Brain Drug Delivery |
|
|
117 | (34) |
|
|
|
|
|
1 Importance and Application of Nanotechnology-Based Brain Drug Delivery Systems |
|
|
117 | (16) |
|
|
133 | (2) |
|
3 Clinical Considerations |
|
|
135 | (1) |
|
4 Ethical and Regulatory Issues |
|
|
136 | (1) |
|
|
137 | (14) |
|
|
137 | (1) |
|
|
138 | (13) |
|
Part 4 Brain-Targeted Experimental Models |
|
|
|
Chapter 8 In Vitro CNS Models |
|
|
151 | (36) |
|
|
|
|
|
151 | (1) |
|
2 Cellular Structure of the BBB |
|
|
152 | (2) |
|
3 Tight Junctions and In Vitro Paracellular Barrier Characterization |
|
|
154 | (3) |
|
|
157 | (12) |
|
5 Comparison of In Vitro Cell Culture Models |
|
|
169 | (1) |
|
6 Conclusions and Future Outlook |
|
|
169 | (18) |
|
|
172 | (1) |
|
|
173 | (14) |
|
Chapter 9 In Vivo/In Situ Animal Models |
|
|
187 | (10) |
|
|
|
187 | (1) |
|
2 Animal Models of Alzheimer's Disease |
|
|
188 | (1) |
|
3 Animal Models of Parkinson's Disease |
|
|
189 | (1) |
|
4 Animal Models of Huntington's Disease |
|
|
189 | (1) |
|
5 Animal Models of Depression |
|
|
189 | (1) |
|
6 Animal Models of Anxiety |
|
|
190 | (1) |
|
7 Animal Models of Schizophrenia |
|
|
190 | (1) |
|
|
191 | (1) |
|
9 Animal Models of Stroke |
|
|
192 | (1) |
|
10 Animal Models of Brain Tumor |
|
|
192 | (1) |
|
|
193 | (4) |
|
|
193 | (1) |
|
|
194 | (3) |
|
Chapter 10 Microdialysis and Brain Perfusion |
|
|
197 | (12) |
|
Margareta Hammarlund-Udenaes |
|
|
|
197 | (2) |
|
2 Techniques in Relation to Measured Entities |
|
|
199 | (1) |
|
|
199 | (4) |
|
4 Open Flow Microperfusion |
|
|
203 | (1) |
|
5 In Situ Brain Perfusion |
|
|
204 | (1) |
|
|
204 | (5) |
|
|
205 | (1) |
|
|
206 | (3) |
|
Chapter 11 Neuroimaging: Techniques and General Applications |
|
|
209 | (18) |
|
|
|
|
|
209 | (1) |
|
|
209 | (2) |
|
|
211 | (3) |
|
4 Magnetic Resonance Imaging |
|
|
214 | (6) |
|
5 Positron Emission Tomography |
|
|
220 | (1) |
|
|
221 | (6) |
|
|
221 | (1) |
|
|
222 | (5) |
|
Part 5 Targeted Treatment Strategies for Neurological Diseases |
|
|
|
|
227 | (14) |
|
|
|
|
227 | (1) |
|
2 Strategies for Brain Drug Delivery in AD Treatment |
|
|
228 | (7) |
|
|
235 | (6) |
|
|
235 | (2) |
|
|
237 | (4) |
|
Chapter 13 Parkinson's Disease |
|
|
241 | (30) |
|
|
|
|
241 | (1) |
|
|
242 | (1) |
|
3 Etiology and Pathogenesis |
|
|
243 | (4) |
|
4 Neuroanatomy of the Basal Ganglia |
|
|
247 | (4) |
|
5 Treatment of Parkinson's Disease |
|
|
251 | (4) |
|
6 Targeted Treatment Strategies for Parkinson's Disease |
|
|
255 | (1) |
|
|
256 | (15) |
|
|
257 | (1) |
|
|
257 | (14) |
|
|
271 | (8) |
|
|
|
|
|
271 | (1) |
|
2 Current Treatment Strategies |
|
|
271 | (1) |
|
3 Saving Penumbral Tissue |
|
|
272 | (1) |
|
4 Neuroprotective Strategies |
|
|
273 | (3) |
|
|
276 | (1) |
|
|
276 | (3) |
|
|
277 | (1) |
|
|
277 | (2) |
|
Chapter 15 Nanotechnology-Based Management of Neurological Autoimmune Diseases |
|
|
279 | (12) |
|
|
|
279 | (1) |
|
2 A Useful Model for Nanoparticle Experiments on CNS Autoimmunity |
|
|
280 | (1) |
|
3 Imaging of Inflammatory Nervous System Disorders by Nanoparticles |
|
|
280 | (2) |
|
4 Nanotechnology in the Treatment of Autoimmune Neurological Disorders |
|
|
282 | (1) |
|
5 Administration of Antiinflammatory Agents |
|
|
282 | (1) |
|
|
283 | (1) |
|
|
284 | (1) |
|
8 Nanotechnology in Nonautoimmune Neuroinflammation |
|
|
284 | (1) |
|
9 Neuroinflammatory Adverse Effects of Nanoparticles |
|
|
285 | (1) |
|
|
286 | (5) |
|
|
286 | (1) |
|
|
287 | (4) |
|
Chapter 16 Infectious Diseases of the Brain |
|
|
291 | (28) |
|
|
|
291 | (1) |
|
|
291 | (10) |
|
3 Consideration of the Treatment of Brain Infections |
|
|
301 | (2) |
|
4 Nanotechnological Approach and Recent Trends in Brain Infection Treatments |
|
|
303 | (5) |
|
|
308 | (11) |
|
|
308 | (1) |
|
|
309 | (10) |
|
|
|
|
319 | (26) |
|
|
|
319 | (1) |
|
|
320 | (3) |
|
3 Conventional Treatment Approaches |
|
|
323 | (1) |
|
4 Blood--Brain Tumor Barrier |
|
|
324 | (2) |
|
|
326 | (3) |
|
6 Nanotechnology-Based Drug Delivery Systems |
|
|
329 | (4) |
|
7 Dual Therapies and Clinical Studies |
|
|
333 | (5) |
|
|
338 | (7) |
|
|
338 | (1) |
|
|
339 | (6) |
Future Outlook |
|
345 | (2) |
Index |
|
347 | |